体积分析评估栓塞预防血管内主动脉修复术后II型内漏的有效性
本研究回顾了2019年6月至2021年7月接受EVAR的腹主动脉瘤患者,A组采用标准EVAR联合预先行栓塞,B组仅行标准EVAR。A组II型内漏发生率显著低于B组(4.8% vs 19.0%),A组免于II型内漏的Kaplan-Meier估计值更优(81.0% vs 95.2%),且A组瘤囊持续回缩,两组均无并发症。作者认为非选择性预先行猪纤维蛋白胶栓塞安全有效,但需更大样本和更长随访的随机对照试验验证。
要点
- A组II型内漏发生率4.8%,显著低于B组的19.0%。
- A组免于II型内漏的Kaplan-Meier估计值为81.0%,B组为95.2%。
- A组瘤囊持续回缩,B组瘤囊体积在12个月内减小但24个月时增加3.07 cm3。
核心结论
- 非选择性预先行猪纤维蛋白胶栓塞在EVAR术中预防II型内漏在短期和中期安全有效。
- 预先行栓塞可导致显著更高的瘤囊回缩率。
- 作者认为需要更大患者群体和更长随访的随机对照试验来验证预先行栓塞预防II型内漏的长期有效性和安全性。
研究设计与样本
- 回顾性研究,纳入2019年6月至2021年7月接受EVAR的腹主动脉瘤患者。
- A组104例接受标准EVAR联合预先行栓塞,B组116例仅接受标准EVAR。
- 主要终点为II型内漏发生率,次要终点包括瘤囊回缩、肠系膜下动脉通畅性、通畅腰动脉数量和全因死亡率。
主要发现
- 技术成功率100%。
- A组II型内漏总体发生率为4.8%,显著低于B组的19.0%。
- A组免于II型内漏的平均时间为22.71个月(95%CI 21.59-23.83个月),B组为19.89个月(95%CI 18.08-21.70个月)。
- Kaplan-Meier估计显示A组免于II型内漏的持续时间显著更长(81.0% vs 95.2%)。
- A组显示持续瘤囊回缩趋势;B组瘤囊体积在12个月内减小,但24个月时增加3.07 cm3。
局限性
- 作者认为需要更大患者群体和更长随访的随机对照试验来验证预先行栓塞预防II型内漏的长期有效性和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The presence of endoleak was associated with the failure of endovascular aortic aneurysm repair (EVAR) treatment. The key to eliminating type II endoleak has shifted from reintervention to prevention. This study aimed to evaluate the effectiveness and safety of applying fibrin sealant to prevent type II endoleak in conjunction with EVAR. METHODS: All patients with abdominal aortic aneurysm who underwent EVAR from June 2019 to July 2021 were reviewed. Patients were grouped as Group A: standard EVAR with preemptive embolization and Group B: standard EVAR alone. The primary endpoint was the incidence of type II endoleak. The secondary endpoints were aneurysm sac regression, the inferior mesenteric artery patency, the numbers of patent lumbar arteries, and all-cause mortality. RESULTS: A total of 104 patients were included in Group A, and 116 were included in Group B. Technical success rate was 100%. The overall incidence of type II endoleak in Group A was significantly lower than that in Group B (4.8% vs 19.0%). The mean time of freedom from type II endoleak was 22.71 months for Group A (95% confidence interval, 21.59-23.83 months) and 19.89 months for Group B (95% confidence interval, 18.08-21.70 months). The Kaplan-Meier estimate of freedom from type II endoleak showed a significantly longer duration of freedom from type II endoleak in Group A (81.0% vs 95.2%). Group A showed a continuous sac regression tendency. In Group B, the sac volume decreased within 12 months but increased by 3.07 cm3 at 24 months. No complications were noted in both groups. CONCLUSIONS: Nonselective preemptive embolization with porcine fibrin sealant during EVAR was safe and effective in preventing type II endoleak in the short and mid-term. Preemptive embolization can lead to a significantly higher sac regression rate. Larger patient populations and longer follow-ups with randomized control designed trials are expected to verify the long-term effectiveness and safety of preemptive embolization in preventing type II endoleak.
引用
- Sun Y, Cai HB, Yang D, et al. Volumetric analysis of effectiveness of embolization for preventing type II endoleaks following endovascular aortic aneurysm repair. J Vasc Surg. 2022. PMID: 36441022. doi:10.1016/j.jvs.2022.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。